Positive Phase III results for lumasiran in the treatment of primary hyperoxaluria type 1 (PH1)

In the single-arm ILLUMINATE-B Phase III trial (n=18), there was a clinically meaningful reduction in urinary oxalate excretion in children <6 years with PH1, with a safety profile matching ILLUMINATE-A (older children and adults).

SPS commentary:

Complete ILLUMINATE-B Phase III results will be presented virtually on October 22nd at the American Society of Nephrology Kidney Week. The MHRA issued an early access to medicines scheme (EAMS) positive scientific opinion for lumasiran for the treatment of PH1 in all age groups in July, based on the findings of the two ILLUMINATE studies.

Biospace Inc.

Resource links:

EAMS scientific opinion